Named for the transversely isotropic shape's natural design and engineering properties, Hexagon Bio’s proprietary discovery platform enables drug development against novel targets, even targets previously considered undruggable. Hexagon’s proprietary algorithms can identify human targets of cryptic natural products, prioritizing among thousands of candidates, and create new chemical entities based on novel chemical scaffolds. This method of identifying novel secondary metabolites and their cognate proteins (therapeutic targets) from genomic data allows Hexagon to bypass traditional screening methods . . .

- Therapeutics
- Antifungals
- Cancer
- Drug Discovery
- Financing
- GEN Edge
- OMICs
- Genomics
- Translational Medicine
- Infectious Diseases
- Metagenomics
Busy Bees: Hexagon Bio Combs Nature’s DNA to Unlock Next-Gen Medicines
The company’s platform uses data science, genomics, synthetic biology, and automation to mine microbial genomes for therapeutics to combat human diseases that have evaded traditional approaches
Hexagon Bio's initial focus is on discovering and developing novel oncology therapeutics and anti-infectives. [Hexagon Bio]